Clinical Scorecard: Radiotheranostic Approaches Using Fibroblast Activation Protein Inhibitors for Imaging Tumor Stroma and Directing Radionuclide Treatment
At a Glance
Category
Detail
Condition
Fibroblast Activation Protein Imaging
Key Mechanisms
Targeting activated fibroblasts and vascular-associated stromal cells in tumors for imaging and therapy.
Target Population
Patients with gastrointestinal cancers, peritoneal disease, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, and biliary tract cancers.
Care Setting
Precision oncology and radiotheranostics.
Key Highlights
FAPI PET provides high lesion-to-background contrast in desmoplastic and low-FDG-avid tumors.
FAPI uptake is not tumor-specific and can occur in various fibro-inflammatory conditions.
Current evidence supports FAPI PET as a complementary imaging method for FAP-targeted radionuclide therapy.
Guideline-Based Recommendations
Diagnosis
Use FAPI PET to detect lesions with low FDG avidity or near high physiologic FDG activity.
Management
Consider FAP-targeted radionuclide therapy based on ligand residence time and lesion characteristics.
Monitoring & Follow-up
Carefully correlate FAPI uptake with clinical history and imaging modalities like CT and MRI.
Risks
Potential for rapid washout of first-generation tracers and heterogeneity of FAP expression.
Patient & Prescribing Data
Patients with tumors expressing fibroblast activation protein.
Therapeutic effectiveness depends on various factors including ligand design and tumor microenvironment.
Clinical Best Practices
Emphasize standardized acquisition and reporting of FAPI PET.
Identify disease-specific indications for FAP-targeted therapies.
Conduct prospective trials measuring management impact and patient-relevant outcomes.
